Abstract
Glioblastoma, one of the best vascularized tumours in humans, appears well suited for an antiangiogenic therapy. VEGF (vascular endothelial growth factor), the most important angiogenesis factor identified to date, is highly expressed in glioblastoma. VEGF is particulary upregulated in palisading cells adjacent to necroses and has subsequently been shown to be hypoxia-inducible in glioma cells in vitro. VEGF-receptor tyrosine kinases, VEGF-R1 (flt-1) and VEGF-R2 (flk-1), are induced in a tumour stage dependent manner during glioma progression and are exclusively expressed in tumour vascular endothelial cells.
These observations suggest that VEGF-receptors are promising targets for tumour endothelial cell specific therapy. The ability to block VEGF-signalling by the VEGF-R2 dominant-negative mutant identifies the VEGF/VEGF-R2 system as a major regulator of glioma angiogenesis. Several experimental approaches demonstrate that in rat gliomas tumour growth can be prevented by the inhibition of angiogenesis. These findings are of pivotal importance for the development of anti-angiogenic therapies in glioblastoma patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barnard RO (1986) The pathology of brain tumours. In: Bee-hen NM (ed) Tumours of the brain. Springer, Berlin Heidelberg New York Tokyo, pp 60–70
Breier G, Albrecht U, Sterrer S, Risau W (1992) Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114: 521–532
Cheng SY, Huang HJS, Nagane M, Ji XD, Wang DG, Shin CCY, Arap W, Huang CM, Cavenee WK (1996) Suppression of glioblastoma angiogenicity and tumourigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 93: 8502–8507
Claffey KP, Brown LF, Delaguila LF, Tognazzi K, Yeo KT, Manseau EJ, Dvorak HF (1996) Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumour growth, angiogenesis, and experimental metastasis. Cancer Res 56: 172–181
Conolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J (1989) Tumour vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84: 1470–1478
De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989–991
Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, Breitman ML (1994) Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8: 1897–1909
Folkman J (1990) What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82: 4–6
Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27–31
Fong GH, Rossant J, Gertsenstein M, Breitman M (1995) Role of the flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66–70
Hatva E, Kaipainen A, Mentula P, Jääskeläinen J, Paetau A, Haltia M, Alitalo K (1995) Expression of endothelial cellspecific receptor tyrosine kinases and growth factors in human brain tumours. Am J Pathol 146: 368–378
Ikeda E, Achen MG, Breier G, Risau W (1995) Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270: 19761–19766
Kim JB, Li B, Winer J, Armanini M, Gillet N, Philipps HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841–844
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306–1309
Millauer B, Wizigmann-Voos S, Schnüren H, Martinez R, Moller N, Risau W, Ullrich A (1993) High affinity VEGF binding and developmental expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835–846
Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative flk-1 mutant. Nature 367: 576–579
Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM (1996) Dominant-negative inhibition of flk-1 suppresses the growth of many tumour types in vivo. Cancer Res 56: 1615–1620
Partanen J, Armstrong E, Mäkelä TP, Korhonen J, Sandberg M, Renkonen R, Knuutila S, Huebner K, Alitalo K (1992) A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol 12: 1698–1707
Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845–847
Plate KH, Breier G, Millauer B, Ullrich A, Risau W (1993) Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumour angiogenesis. Cancer Res 53: 5822–5827
Plate KH, Breier G, Risau W (1994) Molecular mechanisms of developmental and tumour angiogenesis. Brain Pathol 4: 207–218
Plate KH, Breier G, Weich HA, Mennel HD, Risau W (1994) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59: 520–529
Plate KH, Risau W (1995) Angiogenesis in malignant gliomas. Glia 15: 339–347
Rak JW, St Croix BD, Kerbel RS (1995) Consequences of angiogenesis for tumour progression, metastasis and cancer therapy. Anticancer Drugs 6: 3–18
Saleh M, Stacker SA, Wilks AF (1996) Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56: 393–401
Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fuji-wara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Quin Y (1995) Distinct roles of the receptor tyrosine kinases tie-1 and tie-2 in blood vessel formation. Nature 376: 70–74
Schnüren H, Risau W (1993) Expression of tie-2, a member of novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 119: 957–968
Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC (1995) Failure of blood-island formation and vasculogenesis in flk-1-deficient mice. Nature 376: 62–66
Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK (1996) Flk-1 as a target for tumour growth inhibition. Cancer Res 56: 3540–3545
Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz C, Böhlen P (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun 187: 1579–1586
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1997 Springer-Verlag Wien
About this paper
Cite this paper
Stratmann, A., Machein, M.R., Plate, K.H. (1997). Anti-Angiogenic Gene Therapy of Malignant Glioma. In: Ostertag, C.B., Thomas, D.G.T., Bosch, A., Linderoth, B., Broggi, G. (eds) Advances in Stereotactic and Functional Neurosurgery 12. Acta Neurochirurgica Supplements, vol 68. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6513-3_20
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6513-3_20
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-7341-1
Online ISBN: 978-3-7091-6513-3
eBook Packages: Springer Book Archive